Defining Progression in Metastatic Kidney Cancer
3 意见
• 06/26/23
0
0
嵌入
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论